Home » Stocks » Affimed N.V.

Affimed N.V. (AFMD)

Stock Price: $3.47 USD -0.38 (-9.87%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 264.59M
Revenue (ttm) 24.03M
Net Income (ttm) -36.37M
Shares Out 76.25M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $3.47
Previous Close $3.85
Change ($) -0.38
Change (%) -9.87%
Day's Open 3.80
Day's Range 3.23 - 3.94
Day's Volume 1,821,808
52-Week Range 1.42 - 4.91

More Stats

Market Cap 264.59M
Enterprise Value 151.16M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 76.25M
Float 60.77M
EPS (basic) n/a
EPS (diluted) -0.72
FCF / Share -0.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.89M
Short Ratio 2.37
Short % of Float 6.66%
Beta 2.70
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 11.01
PB Ratio 7.82
Revenue 24.03M
Operating Income -36.70M
Net Income -36.37M
Free Cash Flow -34.59M
Net Cash 113.43M
Net Cash / Share 1.48
Gross Margin 100.00%
Operating Margin -152.71%
Profit Margin -151.30%
FCF Margin -143.91%
ROA -26.17%
ROE -115.13%
ROIC 251.10%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.36*
(112.23% upside)
Low
5.70
Current: $3.47
High
10.36
Target: 7.36
*Average 12-month USD price target from 5 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Year20192018201720162015201420132012
Revenue21.3923.742.016.317.563.385.091.17
Revenue Growth-9.88%1080.85%-68.17%-16.5%123.6%-33.52%333.67%-
Gross Profit21.3923.742.016.317.563.385.091.17
Operating Income-32.67-21.05-27.47-32.19-21.99-8.56-16.31-10.60
Net Income-32.37-19.48-30.22-32.22-20.24-0.26-26.10-14.31
Shares Outstanding64.2460.5143.7533.2623.9823.98--
Earnings Per Share-0.50-0.32-0.69-0.97-0.71-0.01-1.76-0.97
Operating Cash Flow-29.4649.56-25.31-31.65-17.99-10.35-5.67-8.65
Capital Expenditures-1.32-0.69-0.59-0.24-0.25-0.25-0.13-0.03
Free Cash Flow-30.7848.87-25.90-31.89-18.24-10.60-5.81-8.68
Cash & Equivalents10410939.8444.8976.7439.734.150.00
Total Debt3.194.777.174.594.583.904.80-
Net Cash / Debt10110432.6740.3072.1635.83-0.650.00
Assets11211643.1648.7479.3241.916.50-
Liabilities73.6976.0511.589.9912.0510.11106-
Book Value38.6740.1331.5838.7567.2731.80-99.22-
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Affimed N.V.
Country Germany
Employees 137
CEO Adolf Hoess

Stock Information

Ticker Symbol AFMD
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AFMD
IPO Date September 12, 2014

Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.